In conclusion, the present study found that the overexpression of hsa-miR-128a augments the effect of pembrolizumab on laryngeal cancer cells and that hsa-miR-128a targets BMI-1 to confer this effect. This evidence concerns the gene BMI1 and laryngeal carcinoma.